Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Olodaterol in COPD
NCT00782509Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of olodaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Forced Expiratory Volume in One Second Area Under Curve 0-3 Hour at 12 weeks and Trough Forced Expiratory Volume in One Second at 12 weeks. Started Feb 2009; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00782509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782509.